

## REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

1. Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, Mullerova H, Lomas DA, Wouters E, Bakke P, Rennard S *et al*: **Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort**. *The European respiratory journal* 2013, **42**(3):636-646.
2. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr., Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC *et al*: **Azithromycin for prevention of exacerbations of COPD**. *The New England journal of medicine* 2011, **365**(8):689-698.
3. ANI Pharmaceuticals Inc: **Terbutaline Sulfate**. In: *US Product Monograph*. Baudette, MN; 2018.
4. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA: **Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease**. *Annals of internal medicine* 1987, **106**(2):196-204.
5. Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MM: **Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease**. *The Cochrane database of systematic reviews* 2006(3):CD001104.
6. AstraZeneca Canada Inc: **Pulmicort Nebuamp (budesonide)**. In: *CA Product Monograph*. Mississauga, ON; 2013.
7. AstraZeneca Canada Inc: **Symbicort Turbuhaler (budesonide / formoterol fumarate dihydrate)**. In: *CA Product Monograph*. Mississauga, ON; 2016.
8. AstraZeneca Canada Inc: **Duaklir Genuair (aclidinium bromide/formoterol fumarate dihydrate)**. In: *CA Product Monograph*. Mississauga, ON; 2017.
9. Astrazeneca Canada Inc: **Daxas (roflumilast)**. In: *CA Product Monograph*. Mississauga, ON; 2017.
10. AstraZeneca Canada Inc: **Pulmicort Turbuhaler (budesonide)**. In: *CA Product Monograph*. Mississauga, ON; 2017.
11. AstraZeneca Canada Inc: **Alvesco (ciclesonide)**. In: *CA Product Monograph*. Mississauga, ON; 2017.
12. AstraZeneca Canada Inc: **Tudorza Genuair (aclidinium bromide)**. In: *CA Product Monograph*. Mississauga, ON; 2017.
13. Astrazeneca Canada Inc: **Bevespi Aerosphere (glycopyrronium / formoterol fumarate dihydrate)**. In: *CA Product Monograph*. Mississauga, ON; 2018.
14. AstraZeneca Canada Inc: **Oxeze Turbuhaler (formoterol fumarate dihydrate)**. In: *CA Product Monograph*. Mississauga, ON; 2018.

15. AstraZeneca Canada Inc: **Bricanyl Turbuhaler (terbutaline sulfate)**. In: *CA Product Monograph*. Mississauga, ON; 2018.
16. AstraZeneca Pharmaceuticals LP: **Symbicort (budesonide / formoterol fumarate dihydrate)**. In: *US Product Monograph*. Wilmington, DE; 2017.
17. AstraZeneca Pharmaceuticals LP: **Tudorza Pressair (aclidinium bromide)**. In: *US Product Monograph*. Wilmington, DE; 2018.
18. AstraZeneca Pharmaceuticals LP: **Daliresp (roflumilast)**. In: *US Product Monograph*. Wilmington, DE; 2018.
19. Aubier M: **Pharmacotherapy of respiratory muscles**. *Clinics in chest medicine* 1988, **9**(2):311-324.
20. Barnes PJ: **New anti-inflammatory targets for chronic obstructive pulmonary disease**. *Nat Rev Drug Discov* 2013, **12**(7):543-559.
21. Barr RG, Bourbeau J, Camargo CA, Ram FS: **Inhaled tiotropium for stable chronic obstructive pulmonary disease**. *The Cochrane database of systematic reviews* 2005(2):CD002876.
22. Basu K, Palmer CN, Tavendale R, Lipworth BJ, Mukhopadhyay S: **Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol**. *The Journal of allergy and clinical immunology* 2009, **124**(6):1188-1194.e1183.
23. BC Renal Agency: **Common oral antimicrobial therapy dosage adjustments for renal function**. In.; 2018.
24. Bleecker ER, Yancey SW, Baitinger LA, Edwards LD, Klotsman M, Anderson WH, Dorinsky PM: **Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma**. *The Journal of allergy and clinical immunology* 2006, **118**(4):809-816.
25. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M: **Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies**. *Lancet (London, England)* 2007, **370**(9605):2118-2125.
26. Bleecker ER, Meyers DA, Bailey WC, Sims AM, Bujac SR, Goldman M, Martin UJ: **ADRB2 polymorphisms and budesonide/formoterol responses in COPD**. *Chest* 2012, **142**(2):320-328.
27. Blondel-Hill E, Fryters S: **Bugs & Drugs**. In. Calgary: Alberta Health Services; 2012.
28. Boardman C, Chachi L, Gavrilu A, Keenan CR, Perry MM, Xia YC, Meurs H, Sharma P: **Mechanisms of glucocorticoid action and insensitivity in airways disease**. *Pulmonary pharmacology & therapeutics* 2014, **29**(2):129-143.
29. Boehringer Ingelheim (Canada) Ltd: **Combivent UDV (ipratropium / salbutamol)**. In: *CA Product Monograph*. Burlington, ON; 2015.

30. Boehringer Ingelheim (Canada) Ltd: **Atrovent HFA (ipratropium)**. In: *CA Product Monograph*. Burlington, ON; 2016.
31. Boehringer Ingelheim (Canada) Ltd: **Combivent Respimat (ipratropium and salbutamol)**. In: *CA Product Monograph*. Burlington, ON; 2016.
32. Boehringer Ingelheim (Canada) Ltd: **Striverdi Respimat (olodaterol)**. In: *CA Product Monograph*. Burlington, ON; 2016.
33. Boehringer Ingelheim (Canada) Ltd: **Spiriva Respimat (tiotropium)**. In: *CA Product Monograph*. Burlington, ON; 2016.
34. Boehringer Ingelheim (Canada) Ltd: **Inspiolto Respimat (tiotropium / olodaterol)**. In: *CA Product Monograph*. Burlington, ON; 2017.
35. Boehringer Ingelheim (Canada) Ltd: **Spiriva (tiotropium)**. In: *CA Product Monograph*. Burlington, ON; 2017.
36. Boehringer Ingelheim (Canada) Ltd: **Spiriva Respimat (tiotropium)**. In: *CA Product Monograph*. Burlington, ON; 2019.
37. Boehringer Ingelheim Pharmaceuticals Inc: **Spiriva Handihaler (tiotropium)**. In: *US Product Monograph*. Ridgefield, CT; 2018.
38. Boehringer Ingelheim Pharmaceuticals Inc: **Stiolto Respimat (tiotropium / olodaterol)**. In: *US Product Monograph*. Ridgefield, CT; 2018.
39. Boehringer Ingelheim Pharmaceuticals Inc: **Striverdi Respimat (olodaterol)**. In: *US Product Monograph*. Ridgefield, CT; 2018.
40. Boehringer Ingelheim Pharmaceuticals Inc: **Spiriva Respimat (tiotropium)**. In: *US Product Monograph*. Ridgefield, CT; 2018.
41. Boehringer Ingelheim Pharmaceuticals Inc: **Spiriva Respimat (tiotropium)**. In: *US Product Monograph*. Ridgefield, CT 2019.
42. Bonini M, Permaul P, Kulkarni T, Kazani S, Segal A, Sorkness CA, Wechsler ME, Israel E: **Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide**. *American journal of respiratory and critical care medicine* 2013, **188**(12):1407-1412.
43. British Columbia Guidelines and Protocols Advisory Committee: **Chronic Obstructive Pulmonary Disease (COPD): Diagnosis and management**. In. Edited by Association BCM. Victoria, BC: Guidelines and Protocols Advisory Committee; 2017.
44. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ: **Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials**. *Lancet (London, England)* 2009, **374**(9691):685-694.

45. Canadian Pharmacists Association: **Corticosteroids: inhaled [CPhA monograph]**. In: *RxTx*. Ottawa, ON; 2016.
46. Canadian Pharmacists Association: **Erythromycin [CPhA monograph]**. In: *RxTx*. Ottawa, ON; 2018.
47. Chong J, Leung B, Poole P: **Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease**. *The Cochrane database of systematic reviews* 2013(11):CD002309.
48. Cosio BG, Shafiek H, Iglesias A, Yanez A, Cordova R, Palou A, Rodriguez-Roisin R, Peces-Barba G, Pascual S, Gea J *et al*: **Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial**. *Chest* 2016, **150**(1):123-130.
49. Covis Pharma: **Alvesco (ciclesonide)**. In: *US Product Monograph*. Zug, Switzerland; 2018.
50. Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F *et al*: **Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD**. *Annals of the American Thoracic Society* 2015, **12**(1):27-34.
51. Criner GJ, Bourbeau J, Diekemper RL, Ouellette DR, Goodridge D, Hernandez P, Curren K, Balter MS, Bhutani M, Camp PG *et al*: **Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline**. *Chest* 2015, **147**(4):894-942.
52. Daskalopoulou SS, Rabi DM, Zarnke KB, Dasgupta K, Nerenberg K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P *et al*: **The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension**. *The Canadian journal of cardiology* 2015, **31**(5):549-568.
53. Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, Cameron R, Shoaib M, Lawrence D, Young D *et al*: **Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study**. *The Lancet Respiratory medicine* 2013, **1**(7):524-533.
54. Delco F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S: **Dose adjustment in patients with liver disease**. *Drug safety* 2005, **28**(6):529-545.
55. Dijkstra A, Koppelman GH, Vonk JM, Bruinenberg M, Schouten JP, Postma DS: **Pharmacogenomics and outcome of asthma: no clinical application for long-term steroid effects by CRHR1 polymorphisms**. *The Journal of allergy and clinical immunology* 2008, **121**(6):1510-1513.
56. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF: **Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials**. *Lancet (London, England)* 2009, **374**(9691):695-703.

57. Finkelstein Y, Bournissen FG, Hutson JR, Shannon M: **Polymorphism of the ADRB2 gene and response to inhaled beta- agonists in children with asthma: a meta-analysis.** *J Asthma* 2009, **46**(9):900-905.
58. Francis RS, Spicer CC: **Chemotherapy in chronic bronchitis. Influence of daily penicillin and tetracycline on exacerbations and their cost.** *British medical journal* 1960, **1**(5169):297-303.
59. Francis RS, May JR, Spicer CC: **Chemotherapy of bronchitis. Influence of penicillin and tetracycline administered daily, or intermittently for exacerbations. A report to the Research Committee of the British Tuberculosis Association by its Bronchitis Subcommittee.** *BMJ* 1961, **2**(5258):979-985.
60. Giacobbe DR, Del Bono V, Trecarichi EM, De Rosa FG, Giannella M, Bassetti M, Bartoloni A, Losito AR, Corcione S, Bartoletti M *et al*: **Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study.** *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2015, **21**(12):1106 e1101-1108.
61. Giubergia V, Gravina L, Castanos C, Chertkoff L: **Influence of beta(2)-adrenergic receptor polymorphisms on asthma exacerbation in children with severe asthma regularly receiving salmeterol.** *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology* 2013, **110**(3):156-160.
62. GlaxoSmithKline: **Breo Ellipta (fluticasone furoate / vilanterol).** In: *US Product Monograph.* Research Triange Park, NC; 2019.
63. GlaxoSmithKline Inc: **Serevent Diskhaler/Diskus (salmeterol).** In: *CA Product Monograph.* Mississauga, ON; 2014.
64. GlaxoSmithKline Inc: **Flovent HFA and Diskus (fluticasone propionate).** In: *CA Product Monograph.* Mississauga, ON; 2016.
65. GlaxoSmithKline Inc: **Incruse Ellipta (umeclidinium).** In: *CA Product Monograph.* Mississauga, ON; 2017.
66. GlaxoSmithKline Inc: **Anoro Ellipta (umeclidinium / vilanterol).** In: *CA Product Monograph.* Mississauga, ON; 2017.
67. GlaxoSmithKline Inc: **Ventolin Diskus (salbutamol sulfate DPI)** In: *CA Product Monograph.* Mississauga, ON; 2017.
68. GlaxoSmithKline Inc: **Ventolin Nebules and Respirator (salbutamol sulfate solution).** In: *CA Product Monograph.* Mississauga, ON; 2017.
69. GlaxoSmithKline Inc: **Arnuity Ellipta (fluticasone furoate DPI).** In: *CA Product Monograph.* Mississauga, ON; 2017.
70. GlaxoSmithKline Inc: **Ventolin HFA (salbutamol sulfate).** In: *CA Product Monograph.* Mississauga, ON; 2017.

71. GlaxoSmithKline Inc: **Advair Diskus (fluticasone propionate / salmeterol)**. In: *CA Product Monograph*. Mississauga, ON; 2018.
72. GlaxoSmithKline Inc: **Flovent HFA and Diskus (fluticasone propionate)**. In: *CA Product Monograph*. Mississauga, ON; 2018.
73. GlaxoSmithKline Inc: **Breo Ellipta (fluticasone furoate / vilanterol)**. In: *CA Product Monograph*. Mississauga, ON; 2019.
74. GlaxoSmithKline LLC: **Incruse Ellipta (umeclidinium)**. In: *US Product Monograph*. Research Triangle Park, NC; 2017.
75. GlaxoSmithKline LLC: **Anoro Ellipta (umeclidinium bromide / vilanterol trifenantate)**. In: *US Product Monograph*. Research Triangle Park, NC; 2017.
76. GlaxoSmithKline LLC: **Advair Diskus (fluticasone propionate / salmeterol)**. In: *US Product Monograph*. Research Triangle Park, NC; 2017.
77. GlaxoSmithKline LLC: **Ventolin HFA (albuterol sulfate)**. In: *US Product Monograph*. Research Triangle Park, NC; 2018.
78. GlaxoSmithKline LLC: **Arnuity Ellipta (fluticasone furoate)**. In: *US Product Monograph*. Research Triangle Park, NC; 2018.
79. GlaxoSmithKline LLC: **Flovent HFA (fluticasone propionate)**. In: *US Product Monograph*. Research Triangle Park, NC; 2019.
80. Global Initiative for Chronic Obstructive Lung Disease: **Pocket guide to COPD diagnosis, management, and prevention. A guide for health care professionals**. In.; 2017.
81. Global Initiative for Chronic Obstructive Lung Disease: **Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. (2018 Report)**. In.; 2018.
82. Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, Criner GJ, Casaburi R, Connett J, Lazarus SC *et al*: **Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy**. *American journal of respiratory and critical care medicine* 2014, **189**(12):1503-1508.
83. Herath SC, Poole P: **Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)**. *The Cochrane database of systematic reviews* 2013(11):CD009764.
84. Hizawa N, Makita H, Nasuhara Y, Betsuyaku T, Itoh Y, Nagai K, Hasegawa M, Nishimura M: **Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD**. *Chest* 2007, **132**(5):1485-1492.
85. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J *et al*: **Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial**. *Lancet (London, England)* 2004, **364**(9444):1505-1512.

86. Johnston RN, McNeill RS, Smith DH, Dempster MB, Nairn JR, Purvis MS, Watson JM, Ward FG: **Five-year winter chemoprophylaxis for chronic bronchitis.** *BMJ* 1969, **4**(5678):265-269.
87. Karner C, Cates CJ: **Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease.** *The Cochrane database of systematic reviews* 2012(4):CD008989.
88. Kim WJ, Oh YM, Sung J, Kim TH, Huh JW, Jung H, Lee JH, Kim EK, Lee JH, Lee SM *et al*: **Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease.** *Lung* 2008, **186**(6):381-386.
89. Kim WJ, Sheen SS, Kim TH, Huh JW, Lee JH, Kim EK, Lee JH, Lee SM, Lee S, Lim SY *et al*: **Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD.** *Respirology (Carlton, Vic)* 2009, **14**(2):260-263.
90. Kim SH, Ye YM, Hur GY, Lee HY, Jee YK, Lee SH, Holloway JW, Park HS: **Effect of beta2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment.** *Yonsei medical journal* 2009, **50**(2):182-188.
91. Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, Nordestgaard BG: **Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population.** *American journal of respiratory and critical care medicine* 2012, **186**(10):975-981.
92. Lee WM: **Drug-induced hepatotoxicity.** *The New England journal of medicine* 2003, **349**(5):474-485.
93. Lemanske RF, Jr., Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, Szeffler SJ, Zeiger RS, Bacharier LB *et al*: **Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.** *The New England journal of medicine* 2010, **362**(11):975-985.
94. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S *et al*: **Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial.** *Jama* 2013, **309**(21):2223-2231.
95. Lipworth BJ, Basu K, Donald HP, Tavendale R, Macgregor DF, Ogston SA, Palmer CN, Mukhopadhyay S: **Tailored second-line therapy in asthmatic children with the Arg(16) genotype.** *Clinical science (London, England : 1979)* 2013, **124**(8):521-528.
96. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF: **Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.** *Lancet (London, England)* 2015, **385**(9971):857-866.
97. Martinez FJ, Rabe KF, Sethi S, Pizzichini E, Mclvor A, Anzueto A, Alagappan VK, Siddiqui S, Rekeda L, Miller CJ *et al*: **Effect of roflumilast and inhaled corticosteroid/long-acting beta2-Agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND).** A

- randomized clinical trial.** *American journal of respiratory and critical care medicine* 2016, **194**(5):559-567.
98. McCormack J CB, Calissi P: **Dosage Adjustment in Renal Impairment.** In: *Therapeutics.* Ottawa, ON: Canadian Pharmacists Association; 2018.
  99. McGeachie MJ, Wu AC, Chang HH, Lima JJ, Peters SP, Tantisira KG: **Predicting inhaled corticosteroid response in asthma with two associated SNPs.** *The pharmacogenomics journal* 2013, **13**(4):306-311.
  100. Mclvor RA: **Chronic Obstructive Pulmonary Disease.** In: *Therapeutics.* Edited by Gray J. Ottawa, ON: Canadian Pharmacists Association; 2017.
  101. McKay SE, Howie CA, Thomson AH, Whiting B, Addis GJ: **Value of theophylline treatment in patients handicapped by chronic obstructive lung disease.** *Thorax* 1993, **48**(3):227-232.
  102. Merck Canada Inc: **Asmanex Twisthaler (mometasone furoate DPI).** In: *CA Product Monograph.* Kirkland, QC; 2018.
  103. Merck Canada Inc: **Zenhale (mometasone furoate / formoterol fumarate dihydrate ).** In: *CA Product Monograph.* Kirkland, QC; 2018.
  104. Merck Sharp & Dohme Corp: **Asmanex HFA (mometasone furoate).** In: *US Product Monograph.* Whitehouse Station, NJ; 2018.
  105. Miravittles M, Anzueto A: **Antibiotic prophylaxis in COPD: Why, when, and for whom?** *Pulmonary pharmacology & therapeutics* 2015, **32**:119-123.
  106. Miravittles M, Soler-Cataluna JJ, Calle M, Molina J, Almagro P, Quintano JA, Trigueros JA, Cosio BG, Casanova C, Antonio Riesco J *et al*: **Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase.** *Archivos de bronconeumologia* 2017, **53**(6):324-335.
  107. Mougey EB, Chen C, Tantisira KG, Blake KV, Peters SP, Wise RA, Weiss ST, Lima JJ: **Pharmacogenetics of asthma controller treatment.** *The pharmacogenomics journal* 2013, **13**(3):242-250.
  108. National Institute for Health and Care Evidence: **Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing [NICE Guideline NG114].** In.; 2018.
  109. National Institute for Health and Care Evidence: **Chronic obstructive pulmonary disease in over 16s: diagnosis and management [NICE guideline NG115].** 2018.
  110. Novartis Pharmaceuticals Canada Inc: **Foradil (formoterol).** In: *CA Product Monograph.* Dorval, QC; 2013.
  111. Novartis Pharmaceuticals Canada Inc: **Onbrez Breezhaler (indacaterol maleate).** In: *CA Product Monograph.* Dorval, QC; 2015.



112. Novartis Pharmaceuticals Canada Inc: **Seebri Breezhaler (glycopyrronium)**. In: *CA Product Monograph*. Dorval, QC; 2016.
113. Novartis Pharmaceuticals Canada Inc: **Ultibro Breezhaler (indacaterol /glycopyrronium)**. In: *CA Product Monograph*. Dorval, QC; 2018.
114. Novartis Pharmaceuticals Corporation: **Seebri Neohaler (glycopyrrolate)**. In: *US Product Monograph*. East Hanover, NJ; 2018.
115. Novartis Pharmaceuticals Corporation: **Utibron Neohaler (indacaterol / glycopyrrolate)**. In: *US Product Monograph*. East Hanover, NJ; 2018.
116. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, Ford G, Gervais A, Goldstein R, Hodder R *et al*: **Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update**. *Canadian respiratory journal* 2007, **14 Suppl B**:5b-32b.
117. O'Donnell DE, Hernandez P, Kaplan A, Aaron S, Bourbeau J, Marciniuk D, Balter M, Ford G, Gervais A, Lacasse Y *et al*: **Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care**. *Canadian respiratory journal* 2008, **15 Suppl A**:1A-8A.
118. Palmer CN, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S: **Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol**. *Thorax* 2006, **61**(11):940-944.
119. Pfizer Canada Inc: **Zithromax (azithromycin)**. In: *CA Product Monograph*. Kirkland, QC; 2017.
120. Pfizer Canada Inc: **Eryc (erythromycin delayed release)**. In: *CA Product Monograph*. Kirkland, QC; 2017.
121. Pfizer Laboratories Div Pfizer Inc: **Zithromax (azithromycin)**. In: *US Product Monograph*. NY, NY; 2018.
122. Pomares X, Monton C, Espasa M, Casabon J, Monso E, Gallego M: **Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations**. *International journal of chronic obstructive pulmonary disease* 2011, **6**:449-456.
123. Purdue Pharma: **Uniphyll (theophylline sr)**. In: *CA Product Monograph*. Pickering, ON; 2017.
124. Rabe KF: **Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease**. *Br J Pharmacol* 2011, **163**(1):53-67.
125. Rabe KF, Fabbri LM, Israel E, Kogler H, Riemann K, Schmidt H, Glaab T, Vogelmeier CF: **Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial**. *The Lancet Respiratory medicine* 2014, **2**(1):44-53.

126. Ram FS, Jones PW, Castro AA, De Brito JA, Atallah AN, Lacasse Y, Mazzini R, Goldstein R, Cendon S: **Oral theophylline for chronic obstructive pulmonary disease.** *The Cochrane database of systematic reviews* 2002(4):CD003902.
127. Ram FS, Jardin JR, Atallah A, Castro AA, Mazzini R, Goldstein R, Lacasse Y, Cendon S: **Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis.** *Respiratory medicine* 2005, **99**(2):135-144.
128. Rebordosa C, Kogevinas M, Guerra S, Castro-Giner F, Jarvis D, Cazzoletti L, Pin I, Siroux V, Wjst M, Anto JM *et al*: **ADRB2 Gly16Arg polymorphism, asthma control and lung function decline.** *The European respiratory journal* 2011, **38**(5):1029-1035.
129. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW: **Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease.** *Archives of internal medicine* 2010, **170**(10):880-887.
130. Sanford JP, Gilbert DN, Sande MA: **The Sanford guide to antimicrobial therapy.** In., Pocket sized edn. Dallas, TX: Antimicrobial Therapy.
131. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA: **Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations.** *American journal of respiratory and critical care medicine* 2008, **178**(11):1139-1147.
132. Sethi S, Jones PW, Theron MS, Miravittles M, Rubinstein E, Wedzicha JA, Wilson R: **Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.** *Respiratory research* 2010, **11**:10.
133. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M *et al*: **Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019.** *The European respiratory journal* 2019, **53**(5).
134. Slankard M, Michelis MA, Mansukhani M, McGoey B, Paige A, Andrews H, Lederer D, Canfield S, DiMango E: **Impact of the Arg 16 allele of the B2AR gene on the effect of withdrawal of LABA in patients with moderate to severe asthma.** *J Asthma* 2016, **53**(8):783-789.
135. Soleimani F, Fahimi F, Adimi Naghan P, Nadji SA, Morowati S, Naderi N, Masjedi MR: **The effect of polymorphisms of beta2 adrenoceptors on response to long-acting beta2 agonists in Iranian asthmatic patients.** *Iran J Allergy Asthma Immunol* 2013, **12**(4):383-390.
136. Tantisira KG, Lake S, Silverman ES, Palmer LJ, Lazarus R, Silverman EK, Liggett SB, Gelfand EW, Rosenwasser LJ, Richter B *et al*: **Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids.** *Human molecular genetics* 2004, **13**(13):1353-1359.
137. Teva Canada Limited: **Theophylline SR.** In: *CA Product Monograph.* Toronto, ON: Teva Canada Limited; 2011.
138. Teva Canada Limited: **Ipratropium UDV.** In: *CA Product Monograph.* Toronto, ON; 2013.

139. Teva Respiratory LLC: **QVAR Redihaler (beclomethasone dipropionate hfa)**. In: *US Product Monograph*. Frazer, PA; 2018.
140. Tsartsali L, Papadopoulos M, Lagona E, Papadimitriou A, Kanaka-Gantenbein C, Louizou E, Kastania A, Priftis KN, Chrousos G: **Association of hypothalamic-pituitary-adrenal axis-related polymorphisms with stress in asthmatic children on inhaled corticosteroids**. *Neuroimmunomodulation* 2012, **19**(2):88-95.
141. Turner S, Francis B, Vijverberg S, Pino-Yanes M, Maitland-van der Zee AH, Basu K, Bignell L, Mukhopadhyay S, Tavendale R, Palmer C *et al*: **Childhood asthma exacerbations and the Arg16 beta2-receptor polymorphism: A meta-analysis stratified by treatment**. *The Journal of allergy and clinical immunology* 2016, **138**(1):107-113 e105.
142. Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, Pelle AJ, Hoogsteden HC, Aerts JG, van der Eerden MM: **Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial**. *The Lancet Respiratory medicine* 2014, **2**(5):361-368.
143. Valeant Canada LP: **QVAR (beclomethasone dipropionate)** In: *CA Product Monograph*. Laval, QC; 2013.
144. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, Beeh KM, Rabe KF, Fabbri LM, Investigators P-C: **Tiotropium versus salmeterol for the prevention of exacerbations of COPD**. *The New England journal of medicine* 2011, **364**(12):1093-1103.
145. Wechsler ME, Lehman E, Lazarus SC, Lemanske RF, Jr., Boushey HA, Deykin A, Fahy JV, Sorkness CA, Chinchilli VM, Craig TJ *et al*: **beta-Adrenergic receptor polymorphisms and response to salmeterol**. *American journal of respiratory and critical care medicine* 2006, **173**(5):519-526.
146. Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, Ameredes BT, Castro M, Craig TJ, Denlinger L *et al*: **Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial**. *Lancet (London, England)* 2009, **374**(9703):1754-1764.
147. Wechsler ME, Yawn BP, Fuhlbrigge AL, Pace WD, Pencina MJ, Doros G, Kazani S, Raby BA, Lanzillotti J, Madison S *et al*: **Anticholinergic vs Long-Acting beta-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial**. *Jama* 2015, **314**(16):1720-1730.
148. Wedzicha JA, Miravittles M, Hurst JR, Calverley PM, Albert RK, Anzueto A, Criner GJ, Papi A, Rabe KF, Rigau D *et al*: **Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline**. *The European respiratory journal* 2017, **49**(3).
149. Yancey SW, Klotsman M, Ortega HG, Edwards LD, Anderson WH: **Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms**. *Current medical research and opinion* 2009, **25**(4):1011-1018.

150. Yang IA, Clarke MS, Sim EH, Fong KM: **Inhaled corticosteroids for stable chronic obstructive pulmonary disease.** *The Cochrane database of systematic reviews* 2012(7):CD002991.
151. Yelensky R, Li Y, Lewitzky S, Leroy E, Hurwitz C, Rodman D, Trifilieff A, Paulding CA: **A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients.** *The pharmacogenomics journal* 2012, **12**(6):484-488.
152. Zacarias EC, Castro AA, Cendon S: **Effect of theophylline associated with short-acting or long-acting inhaled beta2-agonists in patients with stable chronic obstructive pulmonary disease: a systematic review.** *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisiologia* 2007, **33**(2):152-160.
153. Zhou Y, Wang X, Zeng X, Qiu R, Xie J, Liu S, Zheng J, Zhong N, Ran P: **Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year.** *Respirology (Carlton, Vic)* 2006, **11**(5):603-610.
154. Zuurhout MJ, Vijverberg SJ, Raaijmakers JA, Koenderman L, Postma DS, Koppelman GH, Maitland-van der Zee AH: **Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting beta2-agonists: results of the PACMAN cohort.** *Pharmacogenomics* 2013, **14**(16):1965-1971.
155. ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, Knobil K: **Salmeterol plus theophylline combination therapy in the treatment of COPD.** *Chest* 2001, **119**(6):1661-1670.